MD Anderson Cancer Center Uni of Te MDACC
Welcome,         Profile    Billing    Logout  
 4 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Drappatz, Jan
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
10/24
10/24
INSIGhT, NCT02977780: INdividualized Screening Trial of Innovative Glioblastoma Therapy

Recruiting
2
250
US
Temozolomide, Temodar, Neratinib, QBS10072S
Patrick Wen, MD, Eli Lilly and Company, Celgene, Puma Biotechnology, Inc., Accelerate Brain Cancer Cure, Quadriga Biosciences, Inc.
Glioblastoma
03/25
12/25
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
NCT05736406: A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma

Recruiting
1/2
12
US
5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2, Pentalafen®, 5-aminolevulinic acid hydrochloride, Heliance® Solution, 5-ALA PDT, 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2
Hemerion Therapeutics
Primary Glioblastoma
03/25
07/25
NCT05109728: A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Recruiting
1
60
Europe, US
[177Lu]Lu-DOTA-TATE, Lutathera, Lutetium (177Lu)oxodotreotide, Lutetium Lu 177dotatate, [68Ga]Ga-DOTA-TATE, Temozolomide, Radiotherapy
Novartis Pharmaceuticals
Glioblastoma
07/25
07/26
NCT03423628: A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Calendar Jan 2024 - Dec 2024: Data from trial in combination with radiation therapy for brain metastases
Recruiting
1
120
Europe, US
Radiation Therapy, Radiotherapy, Radiation treatment, RT, AZD1390, ATM inhibitor
AstraZeneca
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
04/26
04/26
Drokin, Ashley
NCT04058756: Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Recruiting
1
121
Europe, Canada, US, RoW
PDR001
Novartis Pharmaceuticals
Advanced Solid Tumors
04/30
04/30

Download Options